Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era

Stefan Schreiber, Shomron Ben-Horin, Rieke Alten, René Westhovens, Laurent Peyrin-Biroulet, Silvio Danese, Toshifumi Hibi, Ken Takeuchi, Fernando Magro, Yoorim An, Dong Hyeon Kim, Sang Wook Yoon, Walter Reinisch*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


The coronavirus disease 2019 (COVID-19) pandemic has prompted significant changes in patient care in rheumatology and gastroenterology, with clinical guidance issued to manage ongoing therapy while minimising the risk of nosocomial infection for patients and healthcare professionals (HCPs). Subcutaneous (SC) formulations of biologics enable patients to self-administer treatments at home; however, switching between agents may be undesirable. CT-P13 SC is the first SC formulation of infliximab that received regulatory approval and may be termed a biobetter as it offers significant clinical advantages over intravenous (IV) infliximab, including improved pharmacokinetics and a convenient mode of delivery. Potential benefits in terms of reduced immunogenicity have also been suggested. With a new SC formulation, infliximab provides an additional option for dual formulation, which enables patients to transition from IV to SC administration route without changing agent. Before COVID-19, clinical trials supported the efficacy and safety of switching from IV to SC infliximab for patients with rheumatoid arthritis and inflammatory bowel disease (IBD), and SC infliximab may have been selected on the basis of patient and HCP preferences for SC agents. During the pandemic, patients with rheumatic diseases and IBD have successfully switched from IV to SC infliximab, with some clinical benefits and high levels of patient satisfaction. As patients switched to SC therapeutics, the reduction in resource requirements for IV infusion services may have been particularly welcome given the pandemic, facilitating reorganisation and redeployment in overstretched healthcare systems, alongside pharmacoeconomic benefits and a reduction in exposure to nosocomial infection. Telemedicine and contactless healthcare have been pushed to the forefront during the pandemic, and a lasting shift towards remote patient management and community/home-based drug administration is anticipated. SC infliximab supports the implementation of this paradigm for future improvements of healthcare value delivered. The accumulation of real-world data during the pandemic supports the high level of confidence, with patients, physicians, and healthcare systems benefitting from its uptake. Graphical Abstract: [Figure not available: see fulltext.]

Original languageEnglish
Pages (from-to)2342-2364
Number of pages23
JournalAdvances in Therapy
Issue number6
StatePublished - Jun 2022


FundersFunder number
Arena Pharmaceuticals
Aspire Scientific Limited
Beatrice Tyrrell
Celltrion Healthcare Co., Ltd
Falk Pharma
Kyowa Hakko Kirin Pharma
Lipid Therapeutics
Morris Institute, Procter & Gamble, Prometheus
Nippon Kayaku
Nippon Kayaku, Mochida
Procter & Gamble, Prometheus, Sandoz
Second Genome
Seres Therapeutics
Walter Reinisch
Abbott Laboratories
Bristol-Myers Squibb
Eli Lilly and Company
Astellas Pharma US
Gilead Sciences
Meso Scale Diagnostics
Boehringer Ingelheim
Takeda Pharmaceutical Company
Janssen Pharmaceuticals
Diagnostic Services Manitoba
Pfizer Japan
EA Pharma Co., Ltd.
Arrien Pharmaceuticals
Nippon Kayaku
Seres Therapeutics
Ferring Pharmaceuticals
Medizinische Universität Wien
Dr. Falk Pharma


    • Biobetters
    • CT-P13 SC
    • Coronavirus disease 2019 (COVID-19)
    • Inflammatory bowel disease
    • Innovative biologics
    • Real-world evidence
    • Rheumatic diseases
    • Subcutaneous infliximab
    • Telemedicine


    Dive into the research topics of 'Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era'. Together they form a unique fingerprint.

    Cite this